| Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial A Musa, E Khalil, A Hailu, J Olobo, M Balasegaram, R Omollo, T Edwards, ... PLoS neglected tropical diseases 6 (6), e1674, 2012 | 179 | 2012 |
| Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study AM Musa, B Younis, A Fadlalla, C Royce, M Balasegaram, M Wasunna, ... PLoS neglected tropical diseases 4 (10), e855, 2010 | 120 | 2010 |
| Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase II randomized trial M Wasunna, S Njenga, M Balasegaram, N Alexander, R Omollo, ... PLoS neglected tropical diseases 10 (9), e0004880, 2016 | 89 | 2016 |
| Safety and efficacy of single dose versus multiple doses of AmBisome® for treatment of visceral leishmaniasis in eastern Africa: a randomised trial EAG Khalil, T Weldegebreal, BM Younis, R Omollo, AM Musa, W Hailu, ... PLoS neglected tropical diseases 8 (1), e2613, 2014 | 85 | 2014 |
| Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East … R Omollo, N Alexander, T Edwards, EAG Khalil, BM Younis, AA Abuzaid, ... Trials 12, 1-10, 2011 | 68 | 2011 |
| Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in eastern Africa: results from a pharmacovigilance … R Kimutai, AM Musa, S Njoroge, R Omollo, F Alves, A Hailu, EAG Khalil, ... Clinical drug investigation 37, 259-272, 2017 | 64 | 2017 |
| The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs F Meheus, AA Abuzaid, R Baltussen, BM Younis, M Balasegaram, ... The American Journal of Tropical Medicine and Hygiene 89 (6), 1146, 2013 | 50 | 2013 |
| Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines MEE Elfaki, EAG Khalil, AS De Groot, AM Musa, A Gutierrez, BM Younis, ... Human vaccines & immunotherapeutics 8 (12), 1769-1774, 2012 | 37 | 2012 |
| Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan BM Younis, M Osman, EAG Khalil, F Santoro, S Furini, R Wiggins, ... Molecular therapy 29 (7), 2366-2377, 2021 | 36 | 2021 |
| Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study TPC Dorlo, AE Kip, BM Younis, SJ Ellis, F Alves, JH Beijnen, S Njenga, ... Journal of Antimicrobial Chemotherapy 72 (11), 3131-3140, 2017 | 33 | 2017 |
| Treatment-based strategy for the management of post-kala-azar dermal leishmaniasis patients in the Sudan AM Musa, EAG Khalil, BM Younis, MEE Elfaki, MY Elamin, AOA Adam, ... Journal of tropical medicine 2013, 2013 | 25 | 2013 |
| Revival of a focus of visceral leishmaniasis in central Sudan EAG Khalil, AM Musa, SHH Elgawi, A Meshasha, I Gamar Eldawla, ... Annals of Tropical Medicine & Parasitology 102 (1), 79-80, 2008 | 25 | 2008 |
| Blindness following visceral leishmaniasis: a neglected post-kala-azar complication EAG Khalil, AM Musa, BM Younis, MEE Elfaki, EE Zijlstra, AM Elhassan Tropical doctor 41 (3), 139-140, 2011 | 23 | 2011 |
| Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in eastern Africa: A randomized, controlled, multicountry trial AM Musa, J Mbui, R Mohammed, J Olobo, K Ritmeijer, G Alcoba, ... Clinical Infectious Diseases 76 (3), e1177-e1185, 2023 | 21 | 2023 |
| Surrogate markers of subtle renal injury in patients with visceral leishmaniasis NAA Elnojomi, AM Musa, BM Younis, MEE Elfaki, AM El-Hassan, ... Saudi Journal of Kidney Diseases and Transplantation 21 (5), 872-875, 2010 | 21 | 2010 |
| Blood parasite load as an early marker to predict treatment response in visceral leishmaniasis in Eastern Africa L Verrest, AE Kip, AM Musa, GJ Schoone, HDFH Schallig, J Mbui, ... Clinical Infectious Diseases 73 (5), 775-782, 2021 | 19 | 2021 |
| Leishmania donovani: Genetic diversity of isolates from Sudan characterized by PCR-based RAPD SH Hamad, EAG Khalil, AM Musa, ME Ibrahim, BM Younis, MEE Elfaki, ... Experimental parasitology 125 (4), 389-393, 2010 | 17 | 2010 |
| Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial T Edwards, R Omollo, EAG Khalil, S Yifru, B Musa, A Musa, M Wasunna, ... Trials 12, 1-7, 2011 | 16 | 2011 |
| Expression profiling of Sudanese visceral leishmaniasis patients pre‐and post‐treatment with sodium stibogluconate MAM Salih, M Fakiola, PA Lyons, BM Younis, AM Musa, AM Elhassan, ... Parasite Immunology 39 (6), e12431, 2017 | 15 | 2017 |
| Leishmania: Probable genetic hybrids between species in Sudanese isolates SH Hamad, AM Musa, EAG Khalil, T Abebe, BM Younis, MEE Elthair, ... Journal of Microbiology and Antimicrobials 3 (6), 142-145, 2011 | 15 | 2011 |
